KRAS and ovarian mucinous adenocarcinoma: In ovarian mucinous tumors, cyclin dependent kinase inhibitor 2A (CDKN2A) and KRAS mutations represent the most common genetic alterations in both ovarian mucinous adenocarcinoma and their precursor lesions.